Insulet Corp (PODD) Q4 2025 Earnings Call Highlights: Record Revenue Growth and Strategic …

GuruFocus News

Thu, February 19, 2026 at 4:00 AM GMT+9 4 min read

In this article:

•                                       StockStory Top Pick 
  

  PODD

  +4.55%

This article first appeared on GuruFocus.

**Total Revenue:** $784 million in Q4 2025, a 29% increase in constant currency.

**Full Year Revenue:** Surpassed $2.7 billion, with approximately 30% year-over-year constant currency growth.

**US Revenue:** $568 million in Q4, a 28% increase; $1.9 billion for the year, a 27% growth.

**International Revenue:** $214 million in Q4, a 42% increase; $754 million for the year, a 39% growth.

**Gross Margin:** 72.5% in Q4, a 40 basis point expansion; 71.6% for the year, a 180 basis point expansion.

**Operating Margin:** 18.7% in Q4; 17.6% for the year, a 270 basis point expansion.

**Adjusted EPS:** $1.55 in Q4, a 35% increase; $4.97 for the year, a 53% increase.

**Free Cash Flow:** Over $375 million for 2025, a 24% increase.

**R&D Spending:** Increased by 50% in Q4 and 37% for the full year.

**Cash and Liquidity:** $760 million in cash and full $500 million available under credit facility.

**2026 Revenue Growth Guidance:** 20% to 22% for total company; 21% to 23% for Omnipod revenue.

**2026 Operating Margin Expansion Guidance:** Approximately 100 basis points.

**2026 Adjusted EPS Growth Guidance:** Expected to increase by more than 25%.

Warning! GuruFocus has detected 1 Warning Sign with PODD.

Is PODD fairly valued? Test your thesis with our free DCF calculator.

Release Date: February 18, 2026

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

Insulet Corp (NASDAQ:PODD) achieved its 10th consecutive year of 20% or greater constant currency revenue growth, showcasing the strength of its business model.

The company reported a strong finish to 2025 with total revenues of $784 million in Q4, advancing 29% constant currency, and surpassing $2.7 billion in revenue for the full year.

Insulet Corp (NASDAQ:PODD) experienced record new customer starts in both the US and international markets, with significant growth in type 2 diabetes users.

The company has expanded its prescriber base to over 30,000 healthcare professionals in the US, up approximately 28% year-over-year.

Insulet Corp (NASDAQ:PODD) plans to launch a fully closed-loop system in 2028, which is expected to further expand its market reach and serve the broader primary care population.

Negative Points

Despite strong growth, Insulet Corp (NASDAQ:PODD) faces challenges with new competition entering the market, which could impact its market share.

The company anticipates a deceleration in growth rates for 2026 due to anniversarying the first full year of the US launch of Omnipod for type 2 and annualizing several international launches.

Insulet Corp (NASDAQ:PODD) reported an increase in net interest expense due to debt refinancing, impacting its financials.

The company is investing heavily in R&D, which, while necessary for future growth, could pressure margins in the short term.

There is a need to improve clinical acumen among healthcare providers regarding Insulet Corp (NASDAQ:PODD)'s strong clinical performance, which is currently underappreciated.

 






Story Continues  

Q & A Highlights

Q: What do you think is the most underappreciated part of the Insulet story from an investor perspective? A: Ashley Mcevoy, President and CEO, highlighted four key areas: their tech lead, growing commercial prowess, manufacturing at scale, and financial strength. She emphasized their investment in innovation, the largest sales force in the industry, and their ability to manufacture at scale with high-quality standards. She also noted their strong financial position, with expanding margins and positive cash flow.

Q: How are you thinking about sustaining new patient growth, especially in the US and internationally? A: Ashley Mcevoy stated that Insulet enjoys balanced growth from both the US and international markets, with record new customer starts. The primary source of volume comes from people transitioning from multiple daily injections (MDI). She emphasized the importance of strong clinical performance and affordability in driving growth, particularly in the underpenetrated type 2 diabetes market.

Q: Can you help reconcile script trends with reported revenue? A: Flavia Pease, CFO, explained that total pod data is the best reflection of future revenue. She noted that script data might not capture changes in script fills or seasonality, which can affect revenue. She emphasized the importance of considering these factors when extrapolating from scripts to revenue.

Q: How are you feeling about sustaining 20% growth in light of new competition? A: Ashley Mcevoy expressed confidence in sustaining growth, citing Insulet’s 25-year head start, significant investments, and strong clinical performance. She highlighted the barriers to entry for competitors, such as manufacturing at scale and unlocking the total addressable market (TAM). She also emphasized their commercial prowess and strong relationships with payers and pharmacy benefit managers.

Q: Is Omnipod 5 compatible with the 15-day G7 sensor from Dexcom? A: Eric Benjamin, EVP of Innovation, Strategy, and Digital Products, confirmed that Omnipod 5 is compatible with the 15-day G7 sensor. He emphasized their focus on accelerating sensor integration and noted that they were ready with the 15-day launch from day one.

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Terms and Privacy Policy

Privacy Dashboard

More Info